Celldex Therapeutics reported $598.36M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
AbbVie USD -2.64B 12.35B Sep/2025
Amgen USD 5.13B 1.39B Sep/2025
Bristol-Myers Squibb USD 18.55B 10.06B Sep/2025
Celldex Therapeutics USD 598.36M 533.78M Sep/2025
Glaxosmithkline GBP 7.77B 2.22B Sep/2025
Pfizer USD 92.8B 82.47B Sep/2025
Roche Holding CHF 21.01B 10.84B Dec/2025